Ludovica Ciuffreda, Ursula Cesta Incani, Linda S Steelman, Stephen L Abrams, Italia Falcone, Anais Del Curatolo, William H Chappell, Richard A Franklin, Sabrina Vari, Francesco Cognetti, James A McCubrey, Michele Milella
The RAS/RAF/MEK/ ERK and the PI3K/AKT/mTOR pathways govern fundamental physiological processes, such as cell proliferation, differentiation, metabolism, cytoskeleton reorganization and cell death and survival. Constitutive activation of these signal transduction pathways is a required hallmark of cancer and dysregulation, on either genetic or epigenetic grounds, of these pathways has been implicated in the initiation, progression and metastastic spread of lung cances. Targeting components of the MAPK and PI3K cascades is thus an attractive strategy in the development of novel therapeutic approaches to treat lung cancer, although the use of single pathway inhibitors has met with limited clinical success so far...
2014: Current Pharmaceutical Design